Diana I. Salnikova

Ms. Diana I. Salnikova

Scientific Research Institute of Carcinogenesis, Russian Cancer Research Center NN Blokhin, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DSDiana I. Salnikova
Diana I. Salnikova
VOVarvara Orekhova
Varvara Orekhova
AGAndrey Grechko
Andrey Grechko
ASAntonina Vladimirovna Starodubova
Antonina Vladimirovna Starodubova
Evgeny E. BezsonovEvgeny E. Bezsonov
Evgeny E. Bezsonov
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
Altered mitochondrial function is currently recognized as an important factor in atherosclerosis initiation and progression. Mitochondrial dysfunction can be caused by mitochondrial DNA (mtDNA) mutations, which can be inherited or spontaneously acquired in various organs and tissues, having more or less profound effects depending on the tissue energy status. Arterial wall cells are among the most vulnerable to mitochondrial dysfunction due to their barrier and metabolic functions. In atherosclerosis, mitochondria cause alteration of cellular metabolism and respiration and are known to produce excessive amounts of reactive oxygen species (ROS) resulting in oxidative stress. These processes are involved in vascular disease and chronic inflammation associated with atherosclerosis. Currently, the list of known mtDNA mutations associated with human pathologies is growing, and many of the identified mtDNA variants are being tested as disease markers. Alleviation of oxidative stress and inflammation appears to be promising for atherosclerosis treatment. In this review, we discuss the role of mitochondrial dysfunction in atherosclerosis development, focusing on the key cell types of the arterial wall involved in the pathological processes. Accumulation of mtDNA mutations in isolated arterial wall cells, such as endothelial cells, may contribute to the development of local inflammatory process that helps explaining the focal distribution of atherosclerotic plaques on the arterial wall surface. We also discuss antioxidant and anti-inflammatory approaches that can potentially reduce the impact of mitochondrial dysfunction.

25 April 2024 in Diseases
Verified
Journal Article
Open access
PDF file
DSDiana I. Salnikova
Diana I. Salnikova
NNNikita G Nikiforov
Nikita G Nikiforov
APAnton Postnov
Anton Postnov
Alexander N. OrekhovAlexander N. Orekhov
Alexander N. Orekhov
Rheumatoid arthritis (RA) is a chronic, systemic, and inflammatory autoimmune condition characterized by synovitis, pannus formation (with adjacent bone erosion), and joint destruction. In the perpetuation of RA, fibroblast-like synoviocytes (FLSs), macrophages, B cells, and CD4+ T-cells—specifically Th1 and Th17 cells—play crucial roles. Additionally, dendritic cells, neutrophils, mast cells, and monocytes contribute to the disease progression. Monocytes, circulating cells primarily derived from the bone marrow, participate in RA pathogenesis. Notably, CCR2 interacts with CCL2, and CX3CR1 (expressed by monocytes) cooperates with CX3CL1 (produced by FLSs), facilitating the migration involved in RA. Canonical “classical” monocytes predominantly acquire the phenotype of an “intermediate” subset, which differentially expresses proinflammatory cytokines (IL-1β, IL-6, and TNF) and surface markers (CD14, CD16, HLA-DR, TLRs, and β1- and β2-integrins). However, classical monocytes have greater potential to differentiate into osteoclasts, which contribute to bone resorption in the inflammatory milieu; in RA, Th17 cells stimulate FLSs to produce RANKL, triggering osteoclastogenesis. This review aims to explore the monocyte heterogeneity, plasticity, antigenic expression, and their differentiation into macrophages and osteoclasts. Additionally, we investigate the monocyte migration into the synovium and the role of their cytokines in RA.

10 July 2020 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
SSSadhanendu Samanta
Sadhanendu Samanta
AGAsim Kumar Ghosh
Asim Kumar Ghosh
SGSumit Ghosh
Sumit Ghosh
AIAnastasia A. Ilina
Anastasia A. Ilina
Yulia VolkovaYulia Volkova
Yulia Volkova
AHAlakananda Hajra
Alakananda Hajra
An efficient and practical method has been developed for the synthesis of steroidal imidazo[1,2-a]pyridines as potent antiproliferative agentsviaFeCl3-catalyzed oxidative amination in high yields.

7 October 2020 in Natural Product Research
Verified
Journal Article
Open access
Alexander ScherbakovAlexander Scherbakov
Alexander Scherbakov
OSOlga V. Stasevich
Olga V. Stasevich
DSDiana I. Salnikova
Diana I. Salnikova
OAOlga Andreeva
Olga Andreeva
EMEkaterina Mikhaevich
Ekaterina Mikhaevich
Secoisolariciresinol diglucoside (SDG) is isolated from Linum usitatissimum seeds. The antiproliferative effects of SDG (1) and its derivatives secoisolariciresinol (2) and secoisolariciresinol-4′, 4″-diacetate (3) have been evaluated on MCF-7 breast cancer cells and normal breast epithelial line MCF-10A. Lignan 1 has not shown cytotoxic effects on MCF-7 cells, while derivatives 2 and 3 have inhibited cell growth with IC50 values of 25 and 11 µM, respectively. Estrogen receptor alpha is a key growth driver in MCF-7 cells. Compound 1 did not affect the activity of ERα, while derivatives 2 and 3 showed significant antiestrogenic effects. Compounds 2 and 3 caused apoptosis in the MCF-7 line, determined by the cleavage of PARP. SDG derivative 3 enhanced the effect of doxorubicin. SDG derivatives can be considered as promising agents that exhibit a combined antiestrogen and proapoptotic effect in hormone-dependent breast cancer cells. Graphical Abstract

25 January 2023 in Investigational New Drugs
Verified
Journal Article
Open access
PDF file
Alexander ScherbakovAlexander Scherbakov
Alexander Scherbakov
SVSvetlana K. Vorontsova
Svetlana K. Vorontsova
AKAlvina Khamidullina
Alvina Khamidullina
MMMrdanovic Mrdanovic
Mrdanovic Mrdanovic
OAOlga Andreeva
Olga Andreeva
VSValerii Shirinian
Valerii Shirinian
The promising antitumor effects of progesterone derivatives have been identified in many studies. However, the specific mechanism of action of this class of compounds has not been fully described. Therefore, in this study, we investigated the antiproliferative and (anti)estrogenic activities of novel pentacyclic derivatives and benzylidenes of the progesterone series. The antiproliferative effects of the compounds were evaluated on hormone-dependent MCF7 breast cancer cells using the MTT test. Estrogen receptor α (ERα) activity was assessed by a luciferase-based reporter assay. Immunoblotting was used to evaluate the expression of signaling proteins. All benzylidenes demonstrated inhibitory effects with IC50 values below 10 µM, whereas pentacyclic derivatives were less active. These patterns may be associated with the lability of the geometry of benzylidene molecules, which contributes to an increase in the affinity of interaction with the receptor. The selected compounds showed significant anti-estrogenic potency. Benzylidene 1d ((8 S,9 S,10R,13 S,14 S,17 S)-17-[(2E)-3-(4-fluorophenyl)prop-2-enoyl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthren-3-one) was the most active in antiproliferative and anti-estrogenic assays. Apoptosis induced by compound 1d was accompanied by decreases in CDK4, ERα, and Cyclin D1 expression. Compounds 1d and 3d were characterized by high inhibitory potency against resistant breast cancer cells. Apoptosis induced by the leader compounds was confirmed by PARP cleavage and flow cytometry analysis. Compound 3d caused cell arrest in the G2/M phase. Further analysis of novel derivatives of the progesterone series is of great importance for medicinal chemistry, drug design, and oncology. Graphical Abstract

1 January 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SKStepan Konstantinovich Krymov
Stepan Konstantinovich Krymov
Alexander ScherbakovAlexander Scherbakov
Alexander Scherbakov
DSDiana I. Salnikova
Diana I. Salnikova
DSDanila V. Sorokin
Danila V. Sorokin
LDLyubov G. Dezhenkova
Lyubov G. Dezhenkova
ASAndrey E. Shchekotikhin
Andrey E. Shchekotikhin
1